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ON A MECHANISM OF NITROMIN ACTION 
by 
kδICHI ISHIGAMI 
From the 2nd Surgical Division, Kyoto University Medical School 
(Director : Prof. Dr. Yasumasa Aoyagi) 
It has beri. observed that the therapeutic administration of Nitromin (N.M.0.) 
resulted in many histological changes of neoplastic cels, especially in the midst of 
cell division, for example, the increase of polymorphism~ the alternation and the 
enlargement of nucleus and the diminution of the figure of cell division.9' 1・ 18) BOY-
LAND, E., W. E. HESTON etc. have made clear that after the intravenous injection 
of Nitrogen Must2rd (N.M.) there were increasing development of tumor of the 
lung and lymphosarcoma in a mouse of definite strain.4' rn,) It was also substantiated 
by GJESSING, A. c勺 S.TANAKA etc. that the e妊ectof N. M. and N. M. 0. caused the 
decreased viscosity of the DNA solution.7' 11' •7l According to the results of tracer 
experiment by means of isotopes, N. M. also disturbs the DNA metabolism concern-
ed with the cel division.の However, it is not yet obvious that N. M. 0. acts 
either directly upon the chromosome, i.巴.the DNA metabolism, or indirectly upon 
the same through the medium of enzymic system. The fact that the di妊eredspecies 
of neoplasma exerts an influence upon the effect of antineoplastic drugs is attributed 
to the di妊erectmode of DNA metabolism which is varied with the species of neo-
plastic cels, but more probably to the inhibitory action of these antineoplastic 
agents on the general metabolism which relates to the multiplication of tumor cel. 
When such drugs as vitamin B6, methionine, restamine, glucuronic acid and 
cystine etc. were given simultaneously or somewhat later from the time of injection 
of N. M. or N. M. 0., there was remarkable reduction of harmful by-effects. 18'21> 
Especially, when the administration of N. M. was followed by an injection of 
vitamin Ba within 10-15 minutes, its antineoplastic action has been no more or only 
a litle observed. The present paper records the effect of N. M. 0. on transaminase 
activity which has most close relation to amino acid or protein metabolism among 
the enzymes including vitamin B0, pyridoxine, as the coenzyme. This enzyme is 
able to accelerate the transamination as follows;'• 2• 3• rn, 20l 
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/CH・NH2•COOH /co・COOH CH3CH・NH2・
CH2""-CH2 ・COOH 十 CH3,CO・COOH~~CH2 ""-cH2・COOH －トCOOH
1. glutamic pyruvic acid α－ketoglutaric alanine 
acid acid 
Consequently it plays a considerable role in the synthesis of C四N union, further m 
the protein synthesis. 
Experiment and its Results 
I used such a自nalreaction mixture; I) Enzym~ bu妊ersolution (tissue homo-
genate l : 5)1.0 ml., 2) Phosphate bu佐 rsolution (SやRENSEN)(pH 7,6) 3,5 ml., 
3) 0,2 M Sodium pyruvate solution 1,0 ml., 4) 0,2 M Sodium glutamate solution 
1.0 ml., 5) Nitromin ( Y OSHITOMI) solution ( O,l～0,5 mg/ml/vial) or Aq. dist. 0,5 
ml. and 6) Toluene 0,5 ml. Incubated this for 12 hours at 37°C and measured .the 
amount of decomposed pyruvic acid. Th:e analytical procedure was based on the 
modification by SHIMAZONO and SHIMIZU of th~ FRIEDMANN and HAUGEN method.11) 
All enzyme sources were the fresh neoplastic tissues removed operatively from the 
patients in our clinic. 
The results obtained ・were as shown in Table 1. N.M.O. exhibited the remarka-
ble inhibition upon the transaminase activity which was contained in the neoplastic 
tissues . The higher the concentration of N. M. 0. solution was given, the larger the 
Table 1. Inhibitory efects of N. M. 0. upon the decomposition of pyruvic acid 
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Table 2. Inhibitory efects of N.M.O. upon the transaminase activity 
N. M. 0. 0,2 mg/ml/vial 
Enzyme (gastric cancer) Inhibition o/o 
none added 
14,564 5,964 59,0 
Transaminase alone 8,526 2,811 67,0 
Pyruvic acid oxidase etc. 6.038 3,153 47,6 
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inhibitory action became. But it had no inhibitory action apon the transaminase 
activity of the normal liver tissue. No antagonistic action has been observed in 
adding vitamin Bo to this reaction mixture. The coenzyme of transaminase is not 
vitamin Ba, pyridoxine, itself, but it is pyridoxal phosphoric acid which derived 
from it.16) So that, if the neoplastic cel is unable to synthesize pyridoxal, further 
pyridoxamine from pyridoxine in the above-mentioned experimental conditions, we 
have naturally acquired such results. 
I could not obtained a-ketoglutaric acid and used the unpure tumor cel itself 
as the enzyme source. Therefore I determined the transaminase activity by the 
amount of decomposed pyruvic acid.・ But, in such cases, the amounts of pyruvic 
acid decomposed by pyruvic acid oxidase etc. without the addition of sodium 
glutamate solution into the reaction mixture were also determined. The remarkable 
inhibitory e妊ectof N. M. 0. upon the transaminase activity alone has been also 
proved as shown in Table 2. 
Discussion 
After their wide systematic biochemical researches at National Cancer Institute 
Dr. GREENSTEIN, J.P.巴tc.町 haveconcluded the following enzymic figures of neoplastic 
cel; (1) tumor have qualitatively the same enzymes as normal tissues, ( 2)the 
enzymatic pattern of a twnor is largely independent of its age, of its growth rate 
and of the strain of animal in which it is grown, ( 3)tumors possess a more 
uniform and les diverse chemical pattern than normal tissues. ( 4)when a normal 
fissue become neoplastic, many of the specific functional activities markedly decrease 
or are lost altogether. ( 5)the range of values. for the tumors is usually between 
the extremes of the corresponding values for normal tissues. ( 6)tumor tend to 
converge, enzymatically, to a common type of tissue. Therefore, only from the 
enzymatical viewpoint, so far as the antineoplastic drugs, such as N. M. 0., act only 
upon the enzyme system related to the autonomic atypic multiplication of the 
neoplasma, we cannot expect its e任ectiveantineoplastic action without any severe 
byモ任ectson the systematic administration. Otherwise, we might be hoped that if 
a therapeutic procedure is applicable for one voluntary neoplasma, it would be 
available to some extent for the whole neoplasma. 
CASPERSSON, T. 0. has divided the cel of human neoplasma into two groups.s,s,rn) 
There is no doubt that the inhibitory e任ectof N. M. 0. on transaminase activity 
or its disturbiug action on DNA metabolism are expected for the cell of group A 
which has a great majority of cellular nucleic acid and consists of the pattern that 
is situated outside of cel nest of tumor, around the blood vessels and is infiltrated 
in the adjacent tissues. The administration of N. M. 0. should be also prescribed by 
this relation. 
There are the antagonistic action in the vital body between pyridoxine and N. 
M. or N. M. 0 .It results from the inhibitory e妊ectof N. M. 0. on the transaminase 
activity whiιh needs the modified pyridoxine, pyridoxal phosphoric・ acid, as the 
coenzyme. It is quite interesting that N. M. compounds which contain the pyridoxine 
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structure, such as SK 1424 (Methoxypyridoxyl-N. M.) and SK 2032 (Desoxypyri同
doxyl-N. M.), exhibit the powerful antineoplastic action.的
Summary 
Experimental evidence has been presented to indicate the inhibitory e旺ectof N. 
M. 0. on transaminase activity of the neoplastic tissue removed operatively. Its 
standardized mode of administration and the origin of the antagonistic phenomenon 
between N. M. 0. and pyridoxine havεbeen discussed. It should be emphasized that 
N. M. 0. acts not only as a pure mitosis inhibitor or mutagenic agent, but also 
indirectly through the protein metabolism on the DNA metabolism of tumor: cell. 
References 
I) Altman, K. I. & A. L. Dounce : Non-oxidati-
ve, nonproteolytic enzymes; Transaminase. Ann. 
Rev. Biochem., 21, 51～53, 1952. 2) Ames, S.R., 
P. S. Sarmaゐ C.A. Elvehjem : Transaminase 
and pyridoxine deficiency. J. Biol. Chem., 167, l, 
135～141, 1947. 3) ・ Awapara, J.北 B.Seabe: 
Distribution of transaminase in rat organs. J. 
・ Biol. Chem., 194., 2, 497～502, 1952. 判）Bciyla-
nd, E. & E. S. Horning : The induction of tu-
mors with nitrogen ・mustards. Brit. J. Cancer. 3, 
118～123, 1949. 5) Caspersson, T.ぬ L.Santes-
son : Studies on protein m巴tabolismin the cels 
of epithelial tumours. Acta Radio!. Suppl. XL VI' 
1942. 6) Goldthwait, D.A. : Effect of Nitrogen 
Mustard on nucleic acid metabolism. Proc. Soc. 
Exper. Biol. & Med., 80, 2, 503～504, 1952. 発7)
Gjcssing, A. C.北 Chanutin:The E妊ectof Nitro-
gen Mustard on the viscosity of the mononucle-
.ate. Cancer Res. 6, 593～598, 1946. 8) Green-
stein, J. P.: Biochemist;y of Cancer, 1947, Acade-
mic Press Inc., New York. 9) Hasegawa, T. & 
N. Kawai : The clinical effects of Nitrogen Mus-
tard N-oxide on the cancer of the uterus and 
chorionepithelioma malignum. Nihonrinsho, 10, 
1, 43～45 (931～933), 1952. 持10)Heston, W. 
E. : Induction of pulmonary tomors in strain A 
mice with methyl-bis （~－chloroethyl)amine hydro-
chloride. ]. Nat. Cancer Inst. 10, 125～130, 1950 
ナイトロミン（N.M.0.）を治療の目的で投与する
と，腫癖細胞，特に分裂中の細胞に対して，多形性の
11) Katsunuma, S. : Clinical experiments of Ni-
trogen Mustard N-oxide. Nihonrinsh5, 10, 5, 1～4 
(377～380), ・1952. 12) Kawashima, S. : The 
present aspect of chemotherapy on the malignant 
tumors. Rinsh5, 5, 9, 20～25, 1952. 13) Miyaji, 
T.:. Researches of nucleic acid in tumors. Advan-
ces in medicine (] apanese), 7, 1～74, 1951. 14) 
Shimazono, N. : Vitamin B group and vitamin 
Bi, Nihonigakuzasshi-kabushikikaisha, 1950, To-
kyo. 15) Stang, H. A. : The Schwartzman phe-
nomenon. I. Inhibitory action of Nitrogen Mlls-
tard (HNz). Proc. Soc. Exper. Biol.ゐ Med.,74., 
749～751, 1950. 16) Suda, M. : On the enzyme 
system concerned with vitamin B6・Advancesin 
Enzymology (Japanese), No. 1, 172～216 1949. 
17) Tanaka, S. et al : In但uencesof Nitrogen 
Mustard N-oxide on various enzymes and DNA. 
S5g5igaku, 10, 10, 762～765, 1953. 18) Tasaka, 
S. : Clinical evaiuation of Nitrogen Mustard. 
Saishinigaku, 5, 1, 34～52, 1950. 19) Tashiro, 
S. : Treatment of the neoplastic disease by means 
of Nitrogen Mustard. Geka, 12, 6. 317～325, 195 
O. 20} Umbr巴it,W. W., D. ]. O'kane & I. C. 
Gunsalus : Function of the vitamin B6 group; 
mechanism of transamination. ]. Biol. Chem., 
176, 2, 629～637, 1948. 21) Weisberger, A. S., 
R.もN°.Heinle & B. Levine : The effect of 1 cyst-
ine on Nitrogen Mustard therapy. Amer. J. Med. 
Sc., 24., 2, 20 l～2ll, 1952. 
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N.M.）を一定系のハッカキズミに静脈内注射すると，
肺腫場，淋巴肉腫の発生率を高めることを明らかにし





































1）酵素緩衝液溶液（組織膳砕液1: 5 )l.Occ., 2）燐酸
塩緩衝液（御rcnscn)(pH7,6 3.5cc., 3) 0.2M焦性；m
笹酸ソーダ溶液l.Occ., 4) 0.2M ・グルタミン駿ソーダ
溶液l.Occ.,5）ナイトロミン（吉宮）溶液（O.l～0.5mg
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